key: cord-0852470-6hhiei3w
authors: Praissman, Jeremy; Wells, Lance
title: Proteomics-based Insights into the SARS-CoV-2 Mediated COVID-19 Pandemic: A Review of the First Year of Research
date: 2021-06-04
journal: Mol Cell Proteomics
DOI: 10.1016/j.mcpro.2021.100103
sha: ddbe0b7142a3d21c5f01ab8a3b482762a0f8c2b4
doc_id: 852470
cord_uid: 6hhiei3w

In late 2019, a virus subsequently named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) emerged in China and led to a worldwide pandemic of the disease termed Coronavirus Disease 2019 (COVID-19). The global health threat posed by this pandemic led to an extremely rapid and robust mobilization of the scientific and medical communities as evidenced by the publication of more than ten-thousand peer-reviewed articles and thousands of preprints in the first year of the pandemic alone. With the publication of the initial genome sequence of SARS-CoV-2, the proteomics community immediately joined this effort publishing, to date, more than 100 peer-reviewed proteomics studies and submitting many more preprints to preprint servers. In this review, we focus on peer-reviewed articles published on the proteome, glycoproteome, and glycome of SARS-CoV-2. At a basic level, proteomic studies provide valuable information on quantitative aspects of viral infection course; information on the identities, sites, and microheterogeneity of post-translational modifications; and, information on protein-protein interactions. At a biological systems level, these studies elucidate host cell and tissue responses, characterize antibodies and other immune system factors in infection, suggest biomarkers that may be useful for diagnosis and disease-course monitoring, and help in the development or repurposing of potential therapeutics. Here, we summarize results from selected early studies to provide a perspective on the current rapidly evolving literature.

SARS-CoV-2 is a betacoronavirus that began infecting people in 2019 with the index case identified as a hospitalized patient who initially became ill on December 1, 2019 [1] . The genome of the then unknown etiological agent was rapidly sequenced and made available to other researchers in early January [2] [3] [4] . The SARS-CoV-2 genome reported (29, 903 bases, ss-RNA) was annotated as encoding 26 or more proteins and has high sequence similarity (~80% identity at the nucleotide level) to the extensively studied SARS-CoV-1 virus responsible for SARS outbreaks in 2002 and 2003 as well as to multiple animal coronaviruses [2, [4] [5] [6] .

The SARS-CoV-2 NCBI reference genome was released shortly after publication of the initial genome sequences and contains annotations for 28 encoded proteins. Starting from the 5'-end, the annotated proteins consist of 16 nonstructural proteins (denoted as nsp1-nsp16), translated as components of large polyproteins and then separated by viral proteases, followed by structural proteins and additional ORFs at the 3'-end (Figure 1 ). Putative functions of the encoded proteins were initially inferred by sequence homology to previously studied coronaviruses [2, 4, 5] . The nsp proteins include two with protease functions essential for polyprotein processing -Mpro, also called 3CLpro (3C-like protease, nsp5) and PLpro (papainlike protease, nsp3)as well as the viral replication-transcription complex subunits. Structural proteins encoded include spike (S), envelope (E), membrane (M), and nucleocapsid (N). A number of accessory proteins that have (partially) determined roles in host defense interference, intracellular trafficking, transcription, and replication in related coronaviruses are also encoded [4, 7, 8] . In the context of proteomics, it is important to note that such homology-based annotations provide useful initial models but are necessarily subject to more definitive empirical characterization. This is particularly essential for most RNA viruses due to their comparatively compact genomes and the resulting multiform and multifunction nature of their encoded proteins J o u r n a l P r e -p r o o f driven by evolutionary constraints [9] . Consequently, different groups have used a variety of marginally different annotations in their studies. Researchers have, therefore, continued to work on refining annotations of regulatory elements and encoded polypeptides that may not have been completely characterized by homology-based methods [10] [11] [12] [13] [14] . For example, Finkel et al.

reported 23 unannotated ORFs in their study using ribosome-profiling [10] and Davidson et al. reported that 14% of the transcripts detected in their study do not code for a known ORF and subsequently identified peptides from these transcripts [14] . To our knowledge there is no current definitive database compiling this information and interested readers are directed to the original research articles.

While the genome and preliminary information on the proteome of the SARS-CoV-2 virus itself were being defined, researchers also began determining the host cell proteins required for or facilitative of infection. Angiotensin-converting enzyme 2 (ACE2) was known to be the host cell surface receptor for several other coronaviruses including SARS-CoV-1, and its identity as the host cell surface receptor for SARS-CoV-2 was quickly confirmed [15] [16] [17] [18] . Mature membrane bound ACE2 is a 788 amino acid single-pass type I membrane protein (~91 kDa without PTMs) consisting of an N-terminal peptidase domain, and a C-terminal collectrin-like domain that causes homodimerization at the cell surface and contains the transmembrane helix [19] [20] [21] .

Many viruses additionally utilize host cell proteases and other host cell machinery to enable and facilitate initial cell infection. The protease TMPRSS2 was confirmed as a key factor in SARS-CoV-2 infection in one of the early papers confirming the identity of the cell surface receptor as ACE2 [18] . Researchers have since continued to pursue potential alternative host cell surface receptors, related or alternative proteases (TMPRSS4, Cathepsin B and L), and proteins involved in processes such as endosome maturation (PIKFyve, TPC2) that are critical for infection [18, [22] [23] [24] [25] [26] . However, many questions still remain regarding the role and behavior of host proteases and proteins during infection.

Proteomics-based Insights into SARS-CoV-2

While experimental studies have continued, furthering understanding of the biology of SARS-CoV-2, important parallel efforts have focused on cataloguing and increasing the accessibility of this information. Of particular note to the proteomics community are resources compiling genome sequences, annotations, protein-protein interactions, post-translational modifications, and proteomics data sets. Genome sequences for SARS-CoV-2 from which protein sequences may be derived are available from GISAID [27] , NCBI [28] , EMBL-EBI [29] , and other organizations. The COVID-19 Data Portal (https://www.covid19dataportal.org/) from EMBL-EBI maintains an updated curated collection of SARS-CoV-2 and host proteins and their relationships, and information on pathways and from gene expression studies [29] . A database specific for protein-protein interactions is available from the BioGRID curation project (https://thebiogrid.org/project/3) and may be consulted for continuously updated information [30] .

Many proteomics data sets from relevant studies are available through ProteomeXchange and its subsidiary databases (http://www.proteomexchange.org/) [31] . A number of additional databases contain proteomics data particularly useful for analyzing (or developing assays to analyze) host cell factors, for example: Proteomics DB (https://www.proteomicsdb.org/) [32] , Pax DB (https://pax-db.org/) [33] , the CPTAC Data Portal (https://cptac-dataportal.georgetown.edu/cptacPublic/) [34] , Human Proteome Map (http://www.humanproteomemap.org/) [35] , and The Human Protein Atlas (https://www.proteinatlas.org/) [36] . Glycan information from various studies is compiled in GlyGen (https://www.glygen.org/) [37] . Additionally, glycan and other post-translational modification information is available through PhosphoSitePlus (https://www.phosphosite.org/) [38] .

In the first half of this manuscript, we focus on the virus and its cell entry factors including the preparation of this manuscript and may be of interest for further reading [39] . transitions are also detailed (Supplemental Table 3 overexpresser, Vero E6, Calu-3, and Caco-2) using PRM methods but only in two using a DDAbased method. TMPRSS2 was only detectable in two of the cell lines tested (Calu-3 and Caco-2). Other known and potential viral entry factors including TMPRSS4, CTSB, CTSL, BSG (CD147), and FURIN variously appeared across cell lines in DDA data [41] . Additionally, numerous papers have reported analyses of de novo or publicly available proteomics datasets aimed at characterizing the cell, tissue and bodily fluid distribution of relevant proteins and may be useful as further references [46] [47] [48] [49] .

One longstanding goal in the proteomics field is the development of clinical diagnostics utilizing proteomics, and particularly mass spectrometry-based, methods. This goal is of particular interest during a time of supply-chain disruptions and shortages of necessary reagents for PCRbased assays and other frequently used clinical laboratory methods. However, mass-J o u r n a l P r e -p r o o f spectrometry-based proteomics often suffers from sensitivity, specificity, and throughput issues.

Zecha et al. concluded that the PRM methods developed by their group were inadequate to serve as a reasonable clinical diagnostic platform. Furthermore, considering the literature more broadly (including preprints), they found wide variability among studies suggesting caution in attempting to apply these methods in a clinical setting [41] . Additional studies may be consulted for further information on current progress in developing SARS-CoV-2 diagnostics from nasopharyngeal swabs, gargle solutions, other human samples, and simulated (mock) samples (from in vitro derived mucus and inactivated virus) [43] [44] [45] [50] [51] [52] [53] .

Additional studies not substantially focused on characterization of viral or host cell entry factor peptides but containing lists of detected peptides and further relevant information (often with deposited data sets available in various proteomics databases) have also been published [14, 51, [54] [55] [56] [57] [58] .

Quantitative paper (on SARS-CoV-2 peptide analytical characteristics) establishing a lower-limit of detection (LLOD) and concluding that two tryptic peptides from the nucleocapsid protein provide the best basis for a DDA (with inclusion list) RPLC-MS/MS-based diagnostic platform of the type described. However, these experiments similarly achieved a low rate of detection with diagnosed patient samples (2 / 9 patients or ~22% from a PCR validated cohort) [50] . Relevant peptides from these studies are summarized in Table 1 . Caco-2, using a PRM-based method they developed (discussed in more detail above), finding expression to be more than 1,000x lower in Calu-3 and Caco-2 cells compared to ACE2-A549 cells. TMPRSS2 and other factors involved or putatively involved in host cell entry also varied widely in expression (Zecha et al. Figure 1 , Supplemental Figure S1C , Supplemental Table S1 ) [41] . Hikmet et al. [46] , and Aguiar et al. [61] each carried out immunohistochemical (IHC) analysis of tissue, and protein profiling by western blot and from two publicly available mass spectrometry data sets (one in common to both papers, Kim et al. 2014 [35] . Protein Atlas [36] and the Human Proteome Map [35] and concluded that reproductive consequences of SARS-CoV-2 infection are low given a lack of detectable co-expression of ACE2 and TMPRSS2 at the protein level [49] . One of the most interesting results from these and prior studies, considering the primary respiratory route of viral transmission, has been the difficulty of detecting ACE2 and TMPRSS2 in upper airway samples [61] and other lung tissue samples [46, 47, 61] . Researchers have typically explained this by suggesting that alternative entry factors may exist, noting that ACE2 expression appears to be restricted to a subset of (generally) epithelial cells, and by noting that interferon can upregulate ACE2 expression once infection is established [60] [61] [62] . Among other tissues notable in pathogenesis and symptom presentation, ACE2 and TMPRSS2 were co-detected in multiple intestinal samples [46, 47, 61] and intestine has long been known to be particularly enriched in ACE2 expression [60] .

Proteomics-based Insights into SARS-CoV-2

Studies have also examined changes in host cell entry factor abundance during infection.

Understanding the role of ACE2 modulation during infection is clinically significant because ACE2 is both the viral receptor as well as a lung protective factor (notably in SARS-CoV-1 infection) [18, [62] [63] [64] [65] [66] [67] [68] . However, characterizing this modulation has proven challenging as ACE2 Vero E6, Calu-3, and notably also Caco-2), although they found a decrease in abundance of CTSL (Cathepsin L) over time [41] . Continued work will further refine our understanding of host cell entry factor changes during the course of infection.

Coronavirus proteins, receptors, and other relevant host cell proteins are often posttranslationally modified [72, 73] . Review of the SARS-CoV-2 proteome literature revealed studies of glycosylation, phosphorylation, and at least one report detailing (lysine, arginine, glutamic acid) methylation and proline oxidation on SARS-CoV-2 S and human ACE2 produced in insect cells [74] . The methylation results are somewhat surprising since most methyltransferases are localized to the nucleus although there are reports of aspartic and glutamic acid methylation in the secretory pathway [75] . 

Proteomics-based Insights into SARS-CoV-2

Several SARS-CoV-2 proteins (S, M, E, and certain "orf" proteins such as Orf8 [79, 80] a viroporinand likely Orf7 [81] , as with related coronaviruses), as well as host cell factors important in infection, transit the secretory pathway during expression and thus may be glycosylated by secretory pathway glycosyltransferases. The "S" protein (also called "Spike" or "surface glycoprotein") assembles as homotrimers and coats SARS-CoV-2 virions [16, 17] . The primary binding partner of Spike for host cell entry, ACE2, is also a glycoprotein [15, 18, 82] .

Representing natural targets for both antibodies and inhibitors, there has been substantial interest in both of these proteins and their protein-linked carbohydrate moieties that may shield or otherwise alter protein-protein interactions and protein accessibility. In reviewing glycoproteomic and glycomic studies (particularly preprints), it is important to note that recombinant protein design may lead to non-native modifications (e.g. reports of secretory pathway glycosylation of N). that have previously been widely shown with viruses in general to produce proteins very close in character to those derived from actual viral infections [83, 86] . These studies, by Watanabe et al. studies to date in which glycomics was carried out to refine the topologies of the glycans present [86, 87] . Other studies cited above either utilized proteins not produced in human cell lines [74, 85] or protein other than full-length trimer purified Spike [84, 87] , raising additional questions as to the biological relevance of the glycosylation results obtained with respect to actual SARS-CoV-2 virions in human hosts. The apparent resulting differences provide valuable information to researchers considering antibody or vaccine candidate production in non-human cell lines or using non-trimer purified protein. Finally, it is worth noting that SARS-CoV-2 glycosylation is significantly more host-like than the glycosylation found on many other viruses such as HIV when considering N-glycan processing and density, although high mannose glycans still occur with greater prevalence than on most host proteins [83, 86, 88] .

The two recent studies characterizing the glycosylation of ACE2 form a subset of the SARS-CoV-2 Spike papers [74, 86] and provide a much more complete picture than earlier articles [89] [90] [91] [92] . In particular, Zhao et al. carried out comprehensive glycomics-informed glycoproteomic analysis on a purified soluble version of the protein [86] . ACE2 has 7 "canonical" N-glycosylation sequons, 6 of which were included in the expression construct used in the paper and analyzed in depth. The N-glycosylation of ACE2 was found to be broadly similar to that seen with other human proteins that traffic through the secretory pathway. Only a small amount of Oglycosylation was detected. This detailed analysis of glycosylation also allowed the authors to carry out molecular dynamics simulations of SARS-CoV-2 S glycoprotein bound to ACE2 glycoprotein suggesting that several N-linked glycans on each protein are intimately involved in glycoprotein-glycoprotein interaction (Figure 2) . Additionally, a model of the post-fusion SARS-CoV-2 S glycoprotein was developed showing its distinctive columnar structure and even Nglycan spacing (Figure 2) . Several studies have integrated results from Gordon et al. [56] with other types of host proteome data. Feng et al. [48] integrated the interactome with proteomics datasets from human lung, colon, kidney, liver, and heart, to piece together a more tissue-centric view of the results from Gordon et al. [56] They also extended this analysis with differential quantitative "infectome" data from Bojkova et al. [57] (discussed in detail in the next section) carrying out further PPI network analysis and identifying critical "hubs" and hub proteins, grouped by tissue, and involved in mRNA processing (HNRNPC, SRSF1, HNRNPA3), gene expression (BRD4), the TNF signaling cascade (RIPK1), and the olfactory signaling pathway (REEP5) among others [48] . Zecha et al. [41] integrated the results from Gordon et al. [56] with their own quantitative data on the host proteomes of four relevant cell lines (Human ACE2-A549, Caco-2, Calu-3, and

African green monkey Vero E6) finding 56 interacting host proteins differing quantitatively during infection of Vero E6 cells (Zecha et al. Figure 4C , Supplemental Figure S8D ) [41] . Appelberg et al. [59] also analyzed interactions in Gordon et al. [56] in terms of quantitative transcriptomic and proteomic data (TMT-based) that they generated (Huh7 cells) [59] . Finally, Bouhaddou et al. [101] integrated information from the Gordon et al. [56] interactome with quantitative proteomics and phosphoproteomics as discussed in more detail in next section.

Proteomics-based Insights into SARS-CoV-2

Related to direct protein-protein interactions is the set of proteins regulated or otherwise modulated during infection. This set includes many proteins involved in cell survival and the cell cycle, signaling, host defense (often directly inhibited by pathogenic viruses), cell trafficking, and other critical cellular and host processes [114, 115] . In contrast with studies of protein-protein interactions using techniques like affinity purification, differential quantitative proteomics is subject to several additional confounding factors. Firstviral protein expression increases in particularly permissive host cells dramatically over the course of even relatively short time intervals (8 hours -2 days) which can negatively impact sensitivity and dynamic range in addition to making accurate comparative quantification challenging [58, 101] . Secondin cell culture, different populations of cells will exist concurrently at any given time point (uninfected cells through to apoptotic, necrotic, and fully lysed cells). Thirdin patient samples, quantified proteins must be compared against some standard usually chosen to be "uninfected controls".

This raises questions about how closely the proteomes of small sets of people (in the studies carried out to date) match under ordinary conditions. In this section, we will discuss papers on differential quantitative proteomics of host cell lines in SARS-CoV-2 infection and briefly mention extensions of those studies. We will follow this with discussions of differential quantitative proteomics (and potential biomarkers) from patient samples.

Beginning with the publication of Bojkova et al. [57] , initially available as a preprint in March 2020, seven papers have reported host primary cell or host cell line quantitative differential proteomics in the context of SARS-CoV-2 infection. Six of these papers carried out extensive differential expression, network, pathway, and gene ontology analysis [57-59, 78, 101, 102] (Bouhaddou et al. [101] and Klann et al. [102] primarily in terms of the phosphoproteome) while one examined differential expression in a more cursory fashion [41] . Studies differed in cells or cell line models used (patient PBMCs [78] , Caco-2 from human colon carcinoma [57, 102] , Vero

Proteomics-based Insights into SARS-CoV-2 E6 from African green monkey kidney epithelial cells [58, 101] , and Huh7 from human hepatocyte carcinoma [59] ), time points examined, and analytical techniques and technologies.

Three groups utilized TMT labeling for quantification [41, 59, 78] , one group used mePROD proteomics based on pulsed SILAC and TMT [57] for their first paper and TMT alone for their follow-up paper [102] , and the other two groups used forms of label-free quantification [58, 101] .

Pathways identified in common among various papers include spliceosomal [57, 58, 101, 102] , HIF-1 signaling [41, 57, 59] , innate immune system [41, 59, 78, 101] , and pathways involved in carbon metabolism [57-59, 78, 102] . Many of the host proteins shown to directly interact with viral proteins do not appear centrally in these results presumably since interaction is distinct from regulation. However, for purposes of comparison: HMOX1 (heme degradation) [41, 56, 59, 78] , RIPK1 (NF-kappaB, TNF signaling) [56, 59] , CUL2 & RBX1 (ubiquitination) [57, 59] , and LARP1 (an mTOR-regulated translation repressor) [56, 59, 101] are some proteins shared between PPI studies and these studies (Figure 3 , Table 2 , Supplemental Table 1) . Also of interest, certain pathways such as complement and innate immune activation were detected as differentially regulated only at low MOIs and/or in certain cell lines [41, 59] . Figure 3 , Table 2 , Supplemental Table 1 see CK2), the p38/MAPK pathway (NELFE, HSPB1, STAT1), and cell cycle arrest (CDK2; Figure 3 , Table 2 , Supplemental Table 1 ). Based on the amino acid sequences of mapped sites, kinases and J o u r n a l P r e -p r o o f

Proteomics-based Insights into SARS-CoV-2 kinase families involved were also predicted (CK2, CDK, PKC, MAPK12, CAMK2G, and AKT1/2 among others; Figure 3 , Table 2, Supplemental Table 1 translation initiation, and splicing [102] . Although there is some overlap between proteins revealed by these two studies, there are clear differences in the set of proteins and pathways reported that will not be covered further in this review.

Several additional papers consisting of reanalyses or extensions of data from the papers discussed above have also been published. Feng et al. [48] , as discussed earlier, reanalyzed and extended the data from Bojkova et al. [57] and Gordon et al. [56] to the tissue level. Bock et al. [71] reanalyzed the data from Bojkova et al. [57] using different methods highlighting, for example, the complement cascade in contrast with the original analysis. Many additional papers utilizing these differential host proteomics datasets and results have also been published [10, 102, 116, 117] .

A number of extensive reviews have recently been published containing information on host biofluid proteome changes, potential biomarkers, and immune system response. Therefore, we will not cover the primary literature in these areas in detail here but will briefly summarize several reviews pointing the reader to them for more extensive discussion.

One recent review focused substantially on proteomics was published by Whetton and colleagues. Whetton et al. [118] discuss the complexity of COVID-19, cover relevant proteomics Whetton et al. [118] call attention to the appearance of alternative pathway relevant proteins in a couple of proteomics papers [120, 121] . Additional proteomics papers examining complement system proteins in SARS-CoV-2 infection have since been published [122, 123] (see also Table   2 and Supplemental Table 1 ). Another recent review of note but less focused on proteomics in isolation (among others [124, 125] ), focusing rather on immune response and immunological pathways is by Vabret et al. and expands on the immunology and biochemistry of much of this information [126] . This review also includes information on current clinical trials and therapeutic options. A number of other papers with a proteomic character, including many previously cited in our review (several only in tables), also point to various immune pathways and biofluid proteins and may be consulted for further information [41, 57, 59, 78, 101, 102, 113, [120] [121] [122] [123] [127] [128] [129] .

In less than a year there are now more than 100 directly proteomic-relevant papers already T76  S78  S79  S2  S105 T141 T166, S176, S180, S183, S184, S186, S188, S190, S194, S197, T198, S201, S202, T205, S206 P N PP P P P P P P P PP P P P P P P P P P P P P P P P PP Filopodia P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P P Cytoskeleton modulation CK2 -> CTNNA1, MYH9 … J o u r n a l P r e -p r o o f

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

A new coronavirus associated with human respiratory disease in China

A Novel Coronavirus from Patients with Pneumonia in China

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19

Error thresholds and the constraints to RNA virus evolution

The coding capacity of SARS-CoV-2

The Architecture of SARS-CoV-2 Transcriptome

Pervasive generation of non-canonical subgenomic RNAs by SARS-CoV-2

The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans

Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein

A pneumonia outbreak associated with a new coronavirus of probable bat origin

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Identification of Required Host Factors for SARS-CoV-2 Infection in Human Cells

Genome-wide CRISPR Screens Reveal Host Factors Critical for SARS-CoV-2 Infection

GISAID: Global initiative on sharing all influenza data -from vision to reality

Database resources of the National Center for Biotechnology Information

The European Bioinformatics Institute: empowering cooperation in response to a global health crisis

The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions

The ProteomeXchange consortium in 2017: supporting the cultural change in proteomics public data deposition

ProteomicsDB: a multi-omics and multi-organism resource for life science research

Version 4.0 of PaxDb: Protein abundance data, integrated across model organisms, tissues, and cell-lines

The CPTAC Data Portal: A Resource for Cancer Proteomics Research

A draft map of the human proteome

Proteomics. Tissue-based map of the human proteome

GlyGen: Computational and Informatics Resources for Glycoscience

PhosphoSitePlus, 2014: mutations, PTMs and recalibrations

Mass Spectrometry Techniques in Emerging Pathogens Studies: COVID-19 Perspectives

Shortlisting SARS-CoV-2 Peptides for Targeted Studies from Experimental Data-Dependent Acquisition Tandem Mass Spectrometry Data

Data, Reagents, Assays and Merits of Proteomics for SARS-CoV-2 Research and Testing

Panorama Public: A Public Repository for Quantitative Data Sets Processed in Skyline

A rapid and sensitive method to detect SARS-CoV-2 virus using targeted-mass spectrometry

Development of a Parallel Reaction Monitoring Mass Spectrometry Assay for the Detection of SARS-CoV-2 Spike Glycoprotein and Nucleoprotein

Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work

The protein expression profile of ACE2 in human tissues

A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells

Proteome-wide Data Analysis Reveals Tissue-specific Network Associated with SARS-CoV-2 Infection

Coronavirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues

Proteotyping SARS-CoV-2 Virus from Nasopharyngeal Swabs: A Proof-of-Concept Focused on a 3 Min Mass Spectrometry Window

Mass Spectrometric Identification of SARS-CoV-2 Proteins from Gargle Solution Samples of COVID-19 Patients

Quantitative proteomic dataset from oro-and naso-pharyngeal swabs used for COVID-19 diagnosis: Detection of viral proteins and host's biological processes altered by the infection. Data Brief

Detection of SARS-CoV-2 in nasal swabs using MALDI-MS

Mass-Spectrometric Detection of SARS-CoV-2 Virus in Scrapings of the Epithelium of the Nasopharynx of Infected Patients via Nucleocapsid N Protein

Coronavirus in cat flea: findings and questions regarding COVID-19. Parasit Vectors

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines

Dysregulation in Akt/mTOR/HIF-1 signaling identified by proteotranscriptomics of SARS-CoV-2 infected cells

Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis

Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues

Understanding the renin-angiotensin-aldosterone-SARS-CoV axis: a comprehensive review

Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Dis Transl Med

Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19

Much More Than Just a Receptor for SARS-COV-2. Front Cell Infect Microbiol

The Lung, the Heart, the Novel Coronavirus, and the Renin-Angiotensin System; The Need for Clinical Trials

Angiotensin-converting enzyme 2 prevents lipopolysaccharide-induced rat acute lung injury via suppressing the ERK1/2 and NF-kappaB signaling pathways

The pivotal link between ACE2 deficiency and SARS-CoV-2 infection

Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63

Re-analysis of SARS-CoV-2-infected host cell proteomics timecourse data by impact pathway analysis and network analysis: a potential link with inflammatory response

Post-translational modifications of coronavirus proteins: roles and function

SARS-CoV-2 (COVID-19) structural and evolutionary dynamicome: Insights into functional evolution and human genomics

Mass Spectrometry Analysis of Newly Emerging Coronavirus HCoV-19

Spike Protein and Human ACE2 Reveals Camouflaging Glycans and Unique Post-Translational Modifications. Engineering (Beijing)

Identification and validation of eukaryotic aspartate and glutamate methylation in proteins

Identification of Novel Candidate Epitopes on SARS-CoV-2 Proteins for South America: A Review of HLA Frequencies by Country. Front Immunol

Integrative analyses of SARS-CoV-2 genomes from different geographical locations reveal unique features potentially consequential to host-virus interaction, pathogenesis and clues for novel therapies. Heliyon

Virus-Host Interactome and Proteomic Survey Reveal Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis

Accurate Diagnosis of COVID-19 by a Novel Immunogenic Secreted SARS-CoV-2 orf8 Protein. mBio

Role of the early secretory pathway in SARS-CoV-2 infection

A systemic and molecular study of subcellular localization of SARS-CoV-2 proteins

Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses

Site-specific glycan analysis of the SARS-CoV-2 spike

Deducing the N-and O-glycosylation profile of the spike protein of novel coronavirus SARS-CoV-2

Identification of 22 N-glycosites on spike glycoprotein of SARS-CoV-2 and accessible surface glycopeptide motifs: implications for vaccination and antibody therapeutics

Virus-Receptor Interactions of Glycosylated SARS-CoV-2 Spike and Human ACE2 Receptor

Site-specific characterisation of SARS-CoV-2 spike glycoprotein receptor binding domain

Vulnerabilities in coronavirus glycan shields despite extensive glycosylation

ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis

A proteomic analysis of human bile

Glycoproteomics analysis of human liver tissue by combination of multiple enzyme digestion and hydrazide chemistry

Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor

Developing a Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein Model in a Viral Membrane

Structures and distributions of SARS-CoV-2 spike proteins on intact virions

In situ structural analysis of SARS-CoV-2 spike reveals flexibility mediated by three hinges

Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition

Potential pathogenicity determinants identified from structural proteomics of SARS-CoV and SARS-CoV-2

Impact of glycan cloud on the B-cell epitope prediction of SARS-CoV-2 Spike protein

Molecular Architecture of the SARS-CoV-2 Virus

Beyond Shielding: The Roles of Glycans in the SARS-CoV-2 Spike Protein

The Global Phosphorylation Landscape of SARS-CoV-2 Infection

Growth Factor Receptor Signaling Inhibition Prevents SARS-CoV-2 Replication

Phosphoregulation of Phase Separation by the SARS-CoV-2 N Protein Suggests a Biophysical Basis for its Dual Functions

The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M protein

Structural Insight Into the SARS-CoV-2 Nucleocapsid Protein C-Terminal Domain Reveals a Novel Recognition Mechanism for Viral Transcriptional Regulatory Sequences. Front Chem

Virus entry: open sesame

Virus entry by endocytosis

Genetic Screens Identify Host Factors for SARS-CoV-2 and Common Cold Coronaviruses

Genome-Scale Identification of SARS-CoV-2 and Pancoronavirus Host Factor Networks

A genome-wide CRISPR screen identifies host factors that regulate SARS-CoV-2 entry

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

The current landscape of coronavirus-host protein-protein interactions

COVID-19: viral-host interactome analyzed by network basedapproach model to study pathogenesis of SARS-CoV-2 infection

Human Coronavirus: Host-Pathogen Interaction

Mechanisms of severe acute respiratory syndrome pathogenesis and innate immunomodulation

Sequence-based prediction of SARS-CoV-2 vaccine targets using a mass spectrometry-based bioinformatics predictor identifies immunogenic T cell epitopes

Repurpose Open Data to Discover Therapeutics for COVID-19 Using Deep Learning

Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease

Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition

Ultra-High-Throughput Clinical Proteomics Reveals Classifiers of COVID-19 Infection

Proteomic and Metabolomic Characterization of COVID-19 Patient Sera

Serum protein profiling reveals a landscape of inflammation and immune signaling in early-stage COVID-19 infection

Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level

COVID-19: immunopathogenesis and Immunotherapeutics

The immunology of COVID-19: is immune modulation an option for treatment? The Lancet Rheumatology

Immunology of COVID-19: Current State of the Science

Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment

Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection

Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity

TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells

An 'Arms Race' between the Nonsense-mediated mRNA Decay Pathway and Viral Infections

SARS-CoV-2 multifaceted interaction with the human host

The Nucleocapsid Protein of the SARS Coronavirus: Structure, Function and Therapeutic Potential

Coronavirus envelope protein: current knowledge

The Novel Insight of SARS-CoV-2 Molecular Biology and Pathogenesis and Therapeutic Options

Mitochondria: In the Cross Fire of SARS-CoV-2 and Immunity. iScience

Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection outcome. medRxiv

We thank Oliver C. Grant and Rob Woods for the images in Figure 2 and Professor Bing Chen for the underlying models used. This work was supported in part by a grant from NIH/NIGMS (R01GM130915, LW).J o u r n a l P r e -p r o o f